Reovirus is a promising unmodified double-stranded RNA (dsRNA) anti-cancer oncolytic virus, which is thought to specifically target cells with activated Ras. Although reovirus has been tested in a wide range of preclinical models and has entered early clinical trials, it has not previously been tested for the treatment of human melanoma. Here, we show that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour; intratumoural injection also causes regression of melanoma in a xenograft in vivo model. Reovirus-induced melanoma death is blocked by caspase inhibition and is dependent on constituents of the Ras/RalGEF/p38 pathway. Reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death; a range of inflammatory cytokines and chemokines are released by infected tumour cells, while IL-10 secretion is abrogated. Furthermore, the inflammatory response generated by reovirus-infected tumour cells causes bystander toxicity against reovirus-resistant tumour cells and activates human myeloid dendritic cells (DC) in vitro. Hence, reovirus is suitable for clinical testing in melanoma, and may provide a useful danger signal to reverse the immunologically suppressive environment characteristic of this tumour.
Introduction
Reovirus is a non-enveloped double-stranded RNA (dsRNA) virus of the Reoviridae family, which ubiquitously infects target cells, but is essentially non-pathogenic in humans. It is highly prevalent in the general population, with 50-60% of adults testing positive for reovirus-specific antibodies. 1 The virus is currently under investigation as an anti-cancer agent, as it targets and replicates only in tumour cells with activation of the Ras signalling pathway. 2, 3 This selectivity is thought to arise because Ras-activated tumour cells cannot autophosphorylate PKR in response to the virus; this prevents phosphorylation of eukaryotic initiation factor-2a, which blocks initiation of translation of viral genes in normal cells. Since permissive reovirus replication is also a feature of cells with defects in pathways lying up or downstream of the Ras proteins themselves, this implicates a significant proportion of human tumours as potentially susceptible to reoviral oncolysis. 4, 5 More recent studies have suggested that the determinants of susceptibility to reovirus-induced cell death may be more complex than simple generic activation of the Ras signalling pathway. Norman et al. 6 reported that the activity of the Ras/RalGEF/p38 pathway is the major determinant of susceptibility in transformed NIH 3T3 cells; other work has suggested that Ras activation status does not affect reovirus replication in C26 murine colorectal cancer cells, but does influence their sensitivity to reovirus-induced apoptosis. 7 Viral uncoating and proteolytic disassembly may also play critical roles in effective oncolysis. 8, 9 In preclinical studies, reovirus has been delivered by intratumoural, intravenous or intraperitoneal routes and has shown activity in a wide range of models. These include breast, ovarian, colon, prostate and glioma tumour systems, as well as haematological malignancies, thus confirming the broad potential of reovirus as an anti-cancer agent. [10] [11] [12] [13] Thus far, early phase clinical trials have been completed or are ongoing in prostate cancer, glioma and advanced adult solid malignancies, with no evidence of significant toxicity following intratumoural or intravenous delivery (Vidal et al., unpublished data).
Although a significant percentage of melanomas are defective in Ras or associated signalling pathways, 14, 15 reovirus has not previously been tested against this disease. Melanoma is an increasing clinical problem, with incidence rates across the world approximately doubling over the last 10 years. Although patients with thin primary melanomas are usually cured by surgical resection alone, advanced disease has a very poor prognosis with a median survival of less than 1 year. Standard systemic treatment with chemotherapy and/or cytokine therapy has limited efficacy 16 and novel approaches are urgently needed; hence melanoma represents an appropriate target for assessment of reovirus as an oncolytic agent.
As well as the direct oncolytic potential of the virus, there are features of reovirus-induced cell killing, which may lead to additional bystander immune activation against the tumour. As previously described for other agents, such as herpes simplex virus, 17 vaccinia virus, 18 vesicular stomatitis virus 19 and Newcastle disease virus, 20 viral infection of target tumour cells may enhance recognition by the immune system and help prime generation of an anti-tumour response. If dying tumour cells express tumour-associated antigens (TAAs), which are released in the context of infection, the response against the virus may facilitate coincident innate and subsequent specific priming against TAAs as well as viral epitopes. 21 However, the immune response can inhibit as well as augment therapy during viral oncolysis. Anti-viral antibody responses in particular are likely to restrict activity on repeat administration; indeed, there is evidence that blunting anti-viral antibodies can enhance the anti-tumour potency of reovirus, 22 although completely unrestricted viral replication can also lead to concomitant normal tissue toxicity. 23 In this study, we have tested reovirus against human melanoma in vitro using both cell lines and freshly resected tumour and in vivo in a xenograft model. We have also explored the mechanism of cell death, with special regard to the mode of melanoma killing by reovirus in comparison to current treatment modalities and its potential immunological consequences.
Results

Susceptibility of human melanoma cell lines to reovirus-induced cytotoxicity in vitro
The susceptibility of human melanoma cell lines to reovirus infection and oncolysis was first examined. Mel-888, Mel-624, Mewo and Skmel-28 were left untreated or treated with 10 PFU/cell reovirus and cell viability was examined 48 and 72 h post infection (Figure 1a) . The viability of Mel-888, Mel-624 and Skmel-28 cells was significantly reduced at 48 and 72 h post infection (Pp0.05 by Student's t-test). Although the viability of Mewo cells was reduced at 48 h, this only became statistically significant (P ¼ 0.0041) 72 h post infection. Examination of the morphology of all four untreated cell lines, compared with those infected with 10 PFU/cell reovirus, revealed significant viral-induced cytopathic effect (CPE) at 48 h (Figure 1b ). These data demonstrate that human melanoma cell lines are susceptible to reovirus-induced cell death in vitro.
Next, a more detailed analysis of the sensitivity of an extended panel of seven melanoma cell lines (Skmel-28, Mel-624, Mel-888, Mewo, Colo-829, A-375 and WM-266) and one normal melanocyte cell line (Melan-A) 24 to reovirus cytotoxicity was conducted (Figure 1c) . Three of the cell lines (Skmel-28, A-375 and WM-266) demonstrated exquisite sensitivity, whereas the other four cell lines showed more modest levels of reovirus-mediated cytotoxicity. Melan-A cells were resistant to reovirus even at dilutions of only 1:500 of the initial stock, equivalent to approximately 40 PFU/cell (that is, fourfold higher than the dose of reovirus shown in Figure 1a to be cytotoxic against the melanoma cell lines, Mel-888, Mel-624, Mewo and Skeml-28). Hence, human melanoma cell lines are differentially sensitive to reovirus infection and oncolysis, but significantly more susceptible than normal melanocytes.
Reovirus growth in human melanoma cell lines
To determine whether reovirus replicated in melanoma cell lines, productive infection was assessed by western blot and plaque assays. Plaque assays were used to examine the production of infectious viral progeny in a panel of susceptible melanoma cell lines (Mel-888, Mel-624, Mewo and Skmel-28) and non-susceptible normal melanocytes (Melan-A). All cells were infected with a known concentration of reovirus (10 PFU/cell) and cells/supernatants were harvested 72 h post infection. For each of the melanoma tumour cell lines, there was evidence of viral growth; in direct contrast, the normal melanocyte cell line, Melan-A failed to support viral replication with a fold change in viral titre of only 1.38 ( Figure 2a ). To further examine the kinetics of progeny virus production cells were infected with 10 PFU/cell reovirus for 24, 48, 72 or 96 h and viral replication determined by plaque assay; these experiments demonstrated significant viral replication 24 h after infection, reaching maximum levels at 48 h in all but one of the cell lines tested (Figure 2b ). The absence of increasing levels of virus at later time points probably reflects the significant cell death observed by this stage.
The results demonstrated in Figures 1 and 2a suggest that reovirus replication does not correlate closely with cell sensitivity, as Mewo cells support significant viral replication, while being one of the least sensitive lines to viral killing. However, it is well documented that viral replication may not be required for reovirus-induced cell death; [25] [26] [27] furthermore, studies from our laboratory have demonstrated that ultraviolet (UV)-inactivated, non-replicative reovirus induces significant, though reduced, cell death in these melanoma cell lines (data not shown). Hence, levels of viral replication and cytotoxicity are not inextricably linked.
To confirm the presence of viral proteins in cells which did support viral replication, whole cell lysates were processed 3, 8, 16, 24 and 48 h after reovirus treatment and expression of m, a capsid protein which constitutes 35% of the total viral protein, 28 was examined by western blot (Figure 2b ). Mel-624 and Skmel-28 cells, which were highly susceptible to reovirus-induced cell death, produced detectable levels of the m protein just 16 h post infection. In contrast, reovirus protein was only detected in Mel-888 and Mewo cells 24 and 48 h post infection, respectively. Interestingly, Melan-A cells (which are not susceptible to reovirus-induced cell death ( Figure 1c ) and do not support viral replication (Figure 2a) ) also showed increased expression of the m outer capsid protein 16-48 h post infection (data not shown). While this finding appears to contradict a previous report suggesting that reovirus resistant cells are unable to translate viral transcripts, 3 Marcato et al. 9 have similarly shown that Reovirus therapy for melanoma F Errington et al reovirus protein expression can be detected in both transformed and non-transformed cells. Most importantly, the current data shows a clear difference between malignant and normal melanocytes in the most critical functional readouts of tumour cell cytotoxicity and viral replication.
Reovirus treatment for melanoma in vivo
To examine the therapeutic potential of reovirus in an in vivo preclinical murine model, Mel-888 xenograft tumours were established in athymic nude mice. The tumours were treated with intratumoural injections daily for 5 days of phosphate buffered saline (PBS), UVinactivated or live reovirus once tumours had reached approximately 5 mm in diameter. Tumour growth was monitored as described in Materials and methods and the survival of mice is shown in Figure 3a . At 70 days, 77% of mice treated with live reovirus were alive compared with only 25 and 0% of mice treated with either PBS or UV-inactivated virus, respectively. These differences were statistically significant by the log-rank test (reovirus vs PBS P ¼ 0.011; reovirus vs UV-inactivated reovirus P ¼ 0.0002). Tumour growth of Mel-888 Reovirus therapy for melanoma F Errington et al xenografts is also shown in Figure 3b ; this shows that Mel-888 tumours progressed in six of eight mice treated with PBS, eight of eight mice treated with UV inactivated reovirus and only one of nine mice treated with live reovirus. The inability of UV-inactivated virus to reduce tumour burden in vivo, even though UV-inactivated virus displays some cytotoxicity in vitro, is likely because UV treatment reduces cell killing by three to sixfold in vitro at a PFU of one (data not shown) and, more importantly, UV-inactivated virus is unable to replicate and disseminate through the tumour after injection. No toxicity was seen in any treated animal. These studies confirm that live reovirus can reduce tumour burden and significantly prolong survival after intratumoural delivery to melanoma xenografts.
Role of the Ras signalling pathway in sensitivity to reovirus killing
In view of the data suggesting that the Ras/RalGEF/p38 pathway is a dominant determinant of reovirus susceptibility, 6 we evaluated the effect of small molecule inhibitors of the Ras signalling pathway on reovirus effects in SK-Mel28, Mel-624 and Mel-888 cells. All these small molecules showed limited direct toxicity in all three cell lines (data not shown). Hence, reversal of reovirus-mediated toxicity in addition to the inhibitors implicates significant involvement of the specific Ras signalling pathway in viral killing; direct inhibitor toxicity will, if anything, lead to an underestimation of the magnitude of the effect. The p38 MAPK inhibitor SB202190 reduced reovirus-induced cytotoxicity in all three-cell lines, although this was most evident in Mel-624 and Mel-888 cells ( Figure 4 ). In contrast, MEK1/2 inhibition with U0126 or PD184352 (not shown) did not affect cytotoxicity in any of the cell lines tested. The phosphoinositide (PI) 3-kinase inhibitor LY294002 affected cytotoxicity in Mel-624 cells and, to a lesser extent, SK-Mel-28 cells but did not alter the effect of reovirus against Mel-888 cells ( Figure 4 ). Hence, constituents of the Ras/RalGEF/p38 pathway are implicated in reovirus-induced melanoma killing, although there are differential effects in the different cell lines.
Mode of tumour cell death following reovirus infection
Oncolytic viruses can potentially induce tumour cell death through cell lysis secondary to overwhelming replicating viral burden, 29 through virus-induced apoptosis, 7 or through a combination of the two. Both lytic (that is, necrotic) and apoptotic cell death have been shown, when associated with induction of appropriate immune 'danger signals', to be capable of priming effective anti-tumour immunity. 30 To address the mechanism of reovirus-induced cell death in melanoma, tumour lines were treated with 10 PFU/cell reovirus alone or in combination with ZVAD (a pan-caspase inhibitor of apoptosis) and cell viability determined 48 h post infection. ZVAD alone had no effect, with cell viability remaining comparable to control cells (480%). The viability of cells treated with10 PFU/cell reovirus alone for 48 h was reduced to o20%. Strikingly, the addition of ZVAD to reovirus-infected cells significantly reversed viral-induced cytotoxicity in all cell lines tested, suggesting that reovirus induces melanoma cell death over this time scale predominantly through an apoptotic pathway ( Figure 5 ).
Inflammatory response of tumour cells to reovirus infection
A further key determinant of the potential immunogenicity of tumour cell death is the pattern of cytokine and chemokine production in the tumour microenvironment, which defines the differentiation, proliferation, recruitment and activation of potential immune effector cells. 31 Since other oncolytic viruses have been reported to induce an immunogenic death in tumour cells, 32 we (Figure 6e ). Some tumour cells are known to inherently secrete immunosuppressive cytokines such as interleukin (IL)-10, which can skew the immune response towards a tolerogenic phenotype, thus potentially contributing to immune evasion by cancers. 33, 34 Interestingly, among these four melanoma lines, significant levels of baseline IL-10 secretion by Mel-888 and Skmel-28 were attenuated by reovirus (Figure 6f ). Hence, reovirus not only induces inflammatory cytokine production by infected melanoma cells, but also reduces secretion of immunosuppressive IL-10.
Effects of reovirus on melanoma cells compared with chemotherapy and radiation
Next, we compared the effects of reovirus infection on melanoma cells with the current standard non-surgical treatment modalities of chemotherapy and radiation. 
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Mel-888, Mel-624, Mewo and Skmel-28 cells were treated with 10 PFU/cell reovirus, 1000 mg/ml dacarbazine (DTIC) (a standard chemotherapeutic agent for melanoma), 16 or 30 Gy irradiation and cell viability was determined at 48 and 72 h, (Figure 7a ). Treatment with 10 PFU/cell reovirus significantly reduced cell viability compared with untreated controls in all cell lines as described previously. On direct comparison, radiation was the least effective agent, having minimal cytotoxic effects at the dose and time points examined, while DTIC induced greater cell kill than irradiation in all cell lines, but remained less cytotoxic than reovirus at all time points. MTT assays were used to confirm the effects of these agents at lower doses and longer time points. These studies confirmed that reovirus was more effective than both DTIC and irradiation at doses as low as 2.5 PFU/ cell and time points out to 144 h (data not shown). These data suggest that reovirus may be more cytotoxic than conventional therapeutic strategies for melanoma, at least in vitro.
We also compared reovirus and chemotherapy/radiation for induction of inflammatory cytokines. Melanoma lines were treated with various doses of reovirus, DTIC or radiation and levels of IL-8 (as a representative cytokine induced by all cell lines in response to reovirus) were determined at 48 h (Figure 7b ). While a dosedependent increase in IL-8 production was observed in all cell lines following reovirus infection, neither DTIC nor irradiation induced IL-8 in any cell line. IL-6 production by Mewo cells was similarly restricted to treatment with reovirus ( Figure 7c ). These data suggest that reovirus induces a distinct, potentially immunogenic cell death and is the only treatment modality that may stimulate the production of proinflammatory cytokines within the tumour environment. In separate experiments addressing tumour IL-10 secretion, particularly in response to radiotherapy, we have conversely found an increase in cytokine production on a per cell basis (data not shown), further strengthening a potential role for reovirus as a uniquely immunogenic cytotoxic.
Functional and immunological consequences of inflammatory cytokine production
Production of inflammatory cytokines can potentially support as well as restrict tumour growth; 35 therefore the effect of tumour conditioned media (TCM) from reovirus-infected melanoma cells was investigated. Mel-888, Mel-624, Mewo and Skeml-28 cells were either left untreated or treated with 10 PFU/cell reovirus for 48 h and cell supernatant harvested. This TCM was then added, mixed at a 1:1 ratio with fresh media, to Daudi cells and cell viability determined 120 h later using PI staining; Daudi cells were used specifically in these studies as they are known to be resistant to reovirus infection/oncolysis, 13 ruling out any direct cytotoxic effects of the virus. To begin to address the immunological consequences of inflammatory cytokine production by reovirus-infected tumour cells, Mel-888, Mel-624, Mewo and SKmel-28 cells were infected with 10 PFU/cell reovirus for 48 h and cell supernatants harvested. Reovirus was removed from these supernatants by filtration to exclude any direct viral effects. TCM was then added for 24 h to monocte-derived human myeloid dendritic cells (DC), as key determinants of the immune activation or tolerance instigated by tumours, 36 and their level of activation monitored by phenotypic maturation. Expression of CD80 and CD86 (as representative activation markers) on immature DC, LPS-treated DC (as a positive control) or DC treated with TCM from either non-infected or reovirus-infected melanoma cells is shown in Figure 8b . While TCM from uninfected cells had almost no effect on CD80/86, both activation markers were unregulated in response to reovirus-infected melanoma cells. This data suggests that the inflammatory environment generated by reovirus-infection of melanoma cells is capable of activating human myeloid DC for potential generation of anti-tumour immunity.
Response of primary melanoma cells to reovirus
Since immortal, established cell lines may be a poor representation of clinical disease, we also tested reovirus on melanoma cells freshly isolated from patients. Single cell suspensions of melanoma were derived from resected tumour tissue as described in Materials and methods and adherent cell populations cultured. To confirm that these cells were melanoma in origin (rather than fibroblast or other cell contaminants), the expression of MART-1, a defined melanoma tumour-associated antigen, 37 was examined. Data is shown for tumour cell isolates from two independent donors (MT/05/129 and MT/05/131); the majority of cells stained positive for MART-1 expression, confirming successful isolation of primary melanoma cells (Figure 9a) .
To determine the sensitivity of primary melanoma to reovirus infection and oncolysis, MT/05/129 and MT/ 05/131 cells were treated with 10 PFU/cell and cell viability was examined 24, 48 and 72 h post infection (Figure 9b ). Although no cytotoxicity was seen at 24 h post infection, cell viability was reduced at 48 and 72 h in both donors. Hence, reovirus was an effective cytotoxic agent against primary melanoma, although primary cells were less sensitive than highly proliferative established cell lines.
The extent of viral replication in these cells was also determined. MT/05/129 and MT/05/131 cells were infected with 10 PFU/cell reovirus for 72 h and levels of virus in cells/supernatant quantified by plaque assay. For the two donors, there was a 10-to 40-fold increase in reovirus titre over input virus confirming that viral replication occurred in both primary samples ( Figure 9c) ; as with cytotoxicity, the levels of replication were significantly lower in primary tumour cells than in the melanoma cell lines (Figure 2a) . We also analysed proinflammatory cytokine production by MT/05/129 and MT/05/131 cells 48 h following treatment with 10 PFU/cell reovirus (Figure 9d) . The virus again stimulated the production of Mip-1a, Mip-1b, RANTES Reovirus therapy for melanoma F Errington et al and IL-6 in both donors. Although IL-8 responses were less clear-cut due to significant baseline secretion by both donors, a small increase was also seen over the time course of the experiment. Hence, the inflammatory response of tumour cell lines in response to reovirus is also seen on infection of primary melanoma cells. 
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Discussion
Vertical growth phase malignant melanoma is an extremely aggressive tumour that frequently metastasizes to disseminated sites. 38 Metastatic malignant melanoma (MMM) is incurable with standard surgery, radiotherapy or cytotoxic chemotherapy. Response rates to standard cytotoxic agents, such as DTIC, temozolomide and cisplatin, are low (o20%) and usually of short duration. 16 As MMM frequently expresses tumourassociated antigens, it has been seen as a suitable candidate for the development and testing of immunotherapies. 39 Indeed, a number of agents including interferon-a, interferon-g, IL-2, specific monoclonal antibodies (e.g. anti-CTLA4) and antimelanoma vaccines have been evaluated against MMM. 40 In most of these trials, there have been some patients who have responded to the test agent. Furthermore, preclinical and clinical responses have been shown to correlate with the occurrence of vitiligo, which involves an autoimmune response against normal melanocytes. 41 Indeed, the deliberate establishment of an autoimmune response against normal melanocytes has been proposed as a potential approach for promoting antimelanoma immunity. 42, 43 Therefore, therapies that provoke immune activation in addition to direct tumour-specific cytotoxicity represent rational approaches to the treatment of MMM.
In the studies reported here, we have demonstrated that reovirus is capable of replicating in and killing a range of human melanoma tumour cell lines. Significantly, normal Melan-A melanocytes were resistant to reovirus-mediated cytotoxicity and did not support viral replication (Figures 1, 2) . The antimelanoma effect of reovirus was also apparent in a xenograft model (Figure 3) . Therefore, these data alone support the potential value of reovirus as a direct therapeutic for MMM.
Our finding that reovirus-induced melanoma cell death is caspase-dependent ( Figure 5 ) at the same time as supporting efficient viral replication (Figure 2b ), is consistent with a growing body of evidence describing the signalling cascades triggered by reovirus infection, and the complexity of the multiple downstream cell pathways they activate, which control cell fate as well as potential viral replication. 8, 9, 44 The detailed relationship between the cell's Ras status and the various consequences of infection has not been fully elucidated yet. 5, 44 While our data suggests components of the Ras/ RalGEF/p38 pathway 6 (particularly p38 and in some cell lines PI3K, but not MEK 1/2) are implicated in the reovirus-induced killing of melanoma (Figure 4) , for clinical application the key findings of this study are the sensitivity of melanoma (both cell lines and primary tumours) to reovirus killing and replication, together with the relative resistance of Melan-A normal melanocytes. Sequencing to date of our lines has shown that they are all mutant in the Ras/BRAF pathway (as expected for melanomas 45 ), while Melan-A is normal. Reovirus was also significantly more toxic, at least in vitro, than the current non-surgical treatment modalities of chemotherapy and radiotherapy ( Figure 7) .
As well as describing, for the first time, the in vitro and in vivo potential of reovirus for the treatment of human melanoma, this study addresses some immunological consequences of reovirus-induced human tumour cell killing. Despite intensive investigation of the direct cytotoxic ability of oncolytic viruses, relatively little attention has been paid to their potential to induce antitumour immunity, despite the fact that virus-induced cell death should create an inflammatory, immunologically 'dangerous' environment, with proinflammatory cytokine release, the presence of toll-like receptor ligands and infiltration of cells of the innate immune system. [46] [47] [48] In fact, a role for anti-tumour immunity has been implicated in combination treatment with reovirus plus chemotherapy, although the cellular mechanisms responsible were not defined. 49, 50 Although the immune response to oncolytic viruses will include antiviral as well as anti-tumour priming, which may restrict rather than promote tumour regression, there is a clear body of evidence that concomitant immune priming against TAA can contribute significantly to viral therapy. [17] [18] [19] [20] Much of this data is from animal models rather than human tumours and none has explored reovirus-induced antitumour immune priming as yet.
Here, we show that reovirus induces killing of melanoma cells that is associated with the release of a range of inflammatory cytokines/chemokines (as well as abrogation of immunosuppressive IL-10), which is quite distinct from death following chemotherapy or radiotherapy (Figures 6 and 7) . We investigated the ability of reovirus to stimulate the production of Mip-1a/b, RANTES, IL-8 and IL-6, which play an active role in immune cell recruitment and activation. IL-8, RANTES and Mip-1a/b can recruit a range of immune effector cells including monocytes, dendritic cells, neutrophils and lymphocytes; 51 IL-6 can inhibit the immunosuppressive function of regulatory T cells; 52 RANTES can activate both T cells and natural killer cells and facilitate priming of antigen-specific T cells by acting in concert with costimulatory signals. 53 Hence, the current data ( Figures  6, 7b, c and 9d) demonstrates for the first time that reovirus-induced melanoma death stimulates the production of proinflammatory cytokines/chemokines, while reducing the production of IL-10 ( Figure 6f ). This suggests that reovirus-induced cell killing may reverse the immunosuppressive nature of the tumour environment, facilitate active recruitment of immune effector cells and thereby aid the generation of innate and adaptive anti-tumour immune responses.
To further investigate the functional consequences of inflammatory cytokine production from reovirus Reovirus therapy for melanoma F Errington et al infected melanoma cells, we further determined the effect of this cytokine production on tumour cell growth, as it has previously been reported that cytokines such as IL-6 and IL-8 can promote rather than restrict tumour progression. 54, 55 Figure 8a clearly demonstrates that TCM from infected cells, containing a range of inflammatory cytokines, was directly cytotoxic against reovirus-resistant Daudi cells. Further characterization of the factors responsible for this anti-tumour effect is currently underway.
As a first step towards addressing the potential immunological consequences of reovirus-induced cytokine production by melanoma cells, TCM from reovirusinfected cells was added to human myeloid DC, a pivotal antigen presenting cell essential for priming anti-tumour immune responses. 36 DC underwent phenotypic activation on culture with TCM from reovirus-infected, but not uninfected melanoma cells, showing that soluble factors secreted by infected tumour cells can activate key immune effector cells, potentially facilitating priming of anti-tumour immunity. In support of this hypothesis, preliminary studies from our laboratory have shown (i) that reovirus-infected human tumour cells are a more effective source of TAA than uninfected cells, when loading DC for naïve anti-tumour cytotoxic T cell (CTL) priming in vitro and (ii) that a reovirus-resistant tumour cell line can nevertheless be effectively treated in vivo in an immunocompetent mouse model following intratumoural injection, through a CD8 and natural killerdependent mechanism.
The balance between antiviral and anti-tumour immune priming with oncolytic viral therapy is likely to depend significantly on route of administration; intravenous therapy is associated with a rapid antibody response, careful abrogation of which can support viral persistence and enhance therapy, 22 while direct or regional administration, which more effectively restricts cellular interactions to the otherwise suppressive intratumoural immune milieu, may be particularly effective at breaking tolerance to TAA. Comparative studies in immunocompetent models, and more importantly detailed analysis of treated patients for immune reactivity against viral antigens and TAA, will shed further light on these issues.
In summary, reovirus represents a promising agent for the treatment of human melanoma. The virus killed, and replicated in, freshly resected melanoma as well as immortal cell lines, and was effective therapy following intratumoural injection in a xenograft model. Reovirus killing of melanoma cells was consistently dependent on p38 MAPK, was more potent in vitro than chemotherapy or radiation, and comprised a distinct caspase-dependent, inflammatory cell death, which has the potential to support additional bystander anti-tumour effects through cytokine-induced tumour cytotoxicity and activation of key immune effector cells and immune priming. Reovirus therapy for melanoma F Errington et al
Materials and methods
Cell culture . Human myeloid immature DCs were generated from human peripheral blood mononuclear cells using monocyte adherence as previously described. 56 All cell lines were grown at 371C in a humidified atmosphere containing 5% CO 2 and were routinely tested for, and confirmed free of, mycoplasma. Cs source) or treated with 1000 mg/ml dacarbazine (DTIC).
Reovirus, DTIC and irradiation
Ras pathway inhibitors
Small molecule inhibitors of components of the Ras signalling pathway were used to test their effect on reovirus-mediated cytotoxicity. MEK1/2 inhibitor U0126 (1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene), PI3K inhibitor LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) and p38 MAPK inhibitor SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole) were all obtained from Merck Biosciences, UK. All agents were stored at À20 1C as 10 mM stock solutions in dimethyl sulphoxide, except LY294002, which was stored in ethanol until use.
Measurement of cell viability by propidium iodide staining
Melanoma cells or Daudi cells were seeded at a known density and either infected with different concentrations of reovirus or treated with TCM from non-infected or reovirus-infected melanoma cells (10 PFU/cell, 48 h). Adherent and suspension cells from control and treated cell cultures were harvested, washed with fluorescenceactivated cell sorting (FACS) buffer (PBS, 10% FCS v/v and 1% v/v sodium azide), and stained with 5 ml 0.05 mg/ml PI (Sigma) for 15 min before acquisition. Flow cytometry was performed using a FACSCalibur (Becton Dickinson, Hertfordshire, UK). Cell death was determined by measuring the proportion of cells staining positive for PI.
Measurement of the effect of ZVAD on cell death
To determine the mechanism of reovirus-induced cell death, melanoma cells were seeded at a known density and incubated with 50 mM ZVAD (an irreversible pancaspase inhibitor-Calbiochem, Nottingham, UK) or control medium for 1 hour before reovirus infection. Cell viability was determined using PI staining, as described above.
MTT assay
Tumour cells grown to 80% confluence in 175 cm 2 Falcon flasks (BD Bioscience, Oxford, UK) were harvested, counted and plated in 96-well plates at a density of 1 Â 10 4 cells per well. After 24 h, they were infected with known dilutions of reovirus in DMEM. Control wells received an equivalent volume of unmodified medium. After 96 h incubation, MTT reagent (20 ml of a solution of 5 mg/ml) was added for 5 h and the assay was developed by solubilizing in 100 ml dimethyl sulphoxide and read at 550 nm on a SPECTRAmax 384 plate reader (Molecular Devices, Sunnyvale, CA, USA).
Effect of Ras pathway inhibitors on reoviral cytotoxicity
Cells were plated at a density of 5 Â 10 3 per well in a 96-well plate and the following day, they were exposed to small molecule inhibitors at 10 mM for 2 h. They were then infected with reovirus at approximately the IC 50 dilution for 2 h, after which time the cells were washed and inhibitor-containing medium was added. Cell survival was measured by MTT assay after 96 h.
Western blotting
Melanoma cell lines were either left untreated or infected with 10 PFU/cell reovirus for 3, 8, 16, 24 or 48 h before preparation of whole cell lysates. 57 Proteins from untreated and reovirus-treated cells were electrophoresed (20 mg protein/lane) on an 8% SDS polyacrylamide gel and transferred to a nitrocellulose filter following standard protocols. The reovirus m protein was detected using polyclonal antireovirus goat serum (Oncolytics Biotech Inc.). b-actin was detected using a rabbit polyclonal anti-b-actin antibody (Abcam, Cambridge, UK).
Progeny virus
Cells were infected with reovirus at 10 PFU/cell for 72 h and then cells and supernatants were harvested and subjected to three rounds of freeze/thaw. Viral titre was determined using a standard plaque assay on L929 cells. Fold increase in viral progeny was determined by comparison with levels of input virus.
In vivo activity of reovirus in melanoma xenografts
All procedures were approved by the Mayo Foundation Institutional Animal Care and Use Committee. To establish subcutaneous tumours, 2 Â 10 6 Mel888 cells were injected subcutaneously (100 ml) into the flank region of athymic nude mice (eight per group). Animals were examined daily until the tumour became palpable; at 5 mm, tumours were injected daily for 5 days with 5 Â 10 7 PFU of reovirus, UV-inactivated reovirus or PBS. Thereafter, the tumour diameter was measured thrice weekly using callipers; animals were killed when tumour size was approximately 1.0 Â 1.0 cm in two perpendicular directions. Tumour volume was calculated using the following Equation; p/6 Â d1 Â d2 Â d3.
DC activation
Immature DC were generated as described above and left untreated, treated with 250 ng/ml LPS (Sigma) or cultured with TCM from uninfected melanoma cells or cells treated with 10 PFU/cell reovirus for 48 h. Tumour cell supernatant was subsequently filtered to remove reovirus, using specialized filters (Millipore-successful removal of virus was confirmed by plaque assay), and then added to DC mixed at a 1:1 ratio with fresh DC media. DC were then left for 24 h and the expression of CD80 and CD86 examined by flow cytometry using a FACSCalibur.
ELISA and luminex
Levels of IL-18, IL-10 and IL-6 in tissue culture supernatant were measured by ELISA using matched paired antibodies (BD Biosciences-Pharmingen, Oxford, UK). Mip-1a, Mip-1b and RANTES were detected using luminex technology (Biosource, Nivelles, Belgium) according to the manufacturer's instructions.
Isolation of primary melanoma cells
Freshly isolated melanoma tissue was briefly sterilized in 70% ethanol (30 s) and chopped finely before treatment with 0.1 mg/ml collagenase in DMEM (Gibco), 10 mM HEPES and 1% v/v penicillin/streptomycin (Gibco) for 2 h at 37 1C. Cell suspension was then passed through a 70 mm cell strainer, cells were washed in complete media (DMEM, 10% FCS, 1% HEPES, 1% glutamine and 1% pen/strep) before plating into tissue culture flasks. Cells were left overnight for cells to adhere and non-adherent cells were removed. Adherent cells were cultured in complete media and frozen down in freezing media (90% FCS, 10% dimethyl sulphoxide) prior to use.
Immunofluorescence
Primary melanoma cells were grown on chamber slides (Falcon), washed in PBS and fixed in 4% paraformaldehyde for 30 min. Cells were subsequently washed and permeabilized using 0.3% saponin (15 min at RT) and stained with a mouse monoclonal anti-/MART-1 antibody (1:200 dilution-Santa Cruz, CA, USA) followed by goat anti-mouse FITC conjugated antibody (1:100 dilution-BD Bioscience). Fluorescent images were acquired using a Carl Zeiss Axioplan 2 imaging microscope.
